FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

European countries must match ambition with action — and reward the kind of pharmaceutical innovation they say they want to lead.

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Today, the National Institute for Health and Care Excellence (NICE) published its preliminary optimised recommendation 1 for ribociclib to be used as adjuvant treatment in combination with an ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Our mission is to support high quality educational programs for US HCPs that will improve patient care. We will evaluate professional medical education grant requests that are independent of ...

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From ...

An Open-label, Randomized, Parallel Group, Non-inferiority Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab, ...